Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00128739|
Recruitment Status : Completed
First Posted : August 10, 2005
Last Update Posted : August 29, 2005
|Condition or disease||Intervention/treatment||Phase|
|Graft Vs Host Disease||Drug: Budesonide||Phase 3|
Hide Detailed Description
Graft versus host disease (GVHD) is one of the most common complications of bone marrow transplantation (BMT). Targets of GVHD are the gastro-intestinal tract (GIT) liver and skin, causing severe diarrhea and mucosal aberration and hepatitis that can cause life threatening liver failure. As a result of the mucosal aberration and the general immuno-suppression, caused both by the GVHD process itself and by the anti GVHD therapy, these patients are highly susceptible for severe, life threatening infections that usually originate from the GIT. Systemic steroids are the backbone of anti GVHD therapy. However, in GVHD systemic steroids have to be administered for a prolonged duration and in high doses, thus causing prolonged immune suppression, and exposing the patients to steroid side effects such as hypertension, diabetes, cataract formation etc.
Budesonide is a steroid that combines topical anti-inflammatory activity with high first-pass hepatic extraction. It was shown to be effective in treatment of inflammatory bowel disease with results slightly less then systemic steroids and fewer steroid-related adverse reactions. Except for its influence on the gut, budesonide was also shown to benefit inflammatory hepatic conditions such as primary biliary cirrhosis, liver transplantation and autoimmune hepatitis. Recently, it has been shown that budesonide is an effective treatment in acute GIT GVHD. The investigators propose to evaluate the effect of budesonide in GIT and hepatic GVHD with the following study.
Twelve patients after allogenic peripheral blood stem cell transplantation (PBSCT) with grade >= 2 GIT and/or hepatic GVHD will be prospectively compared to 12 placebo controls.
- Clinical and biopsy proven grade >/= 2 GIT AND/OR hepatic GVHD.
- Preventive antimicrobial treatment (with the exception of Resprim) or somatostatin in the GIT GVHD patients.
- Anti-GVHD treatment other then steroids (maximal dose ≤ 2 mg/kg methylprednisolone) and cyclosporine A or tacrolimus.
All patients will be assessed for GVHD scoring (organ and general) according to standard criteria and tested before inclusion for the following parameters –
- Colon and/or liver biopsy GVHD staging (including number of crypt abscesses).
- Liver function tests - blood albumin, AST, ALT, GGTP, Alk Phos, LDH, bilirubin, coagulation function, cholesterol.
- Stool - volume and frequency.
- Radiological – CT scan for mucosal edema, wall thickening and ascites.
- Kidney function tests – blood creatinine, creatinine clearance.
- Blood pressure.
- Fasting blood glucose. If normal – oral glucose tolerance test, glycosylated hemoglobin.
- Ophthalmologist evaluation for cataract formation and IOP.
- GIT absorption assessment - xylose absorption.
- Microbiological - stool culture and stool for CDT, CMV PCR, culture for CMV in blood and urine.
- Bone density – by ultrasound.
After inclusion the patients will be treated with budesonide 9 or 15mg per day in divided doses or placebo. Other anti-GVHD treatment or ursodeoxycholic acid will not be withheld but tapering off will be tried.
- LFT, albumin, PT, cholesterol, renal function, stool volume and frequency, CMV culture and PCR, clinical GVHD staging - every 2 weeks.
- Xylose test – every month.
- Ophthalmologist evaluation, diabetes control and CT scan – every 3 months.
- GIT and/or liver biopsy for GVHD staging (including number of crypt abscesses) and CMV PCR, bone density – every 6 months
- Blood, urine and stool culture during every febrile episode.
Study duration: 14 weeks.
- Hospitalizations: due to GVHD and/or due to infections.
- Overall and GIT or hepatic GVHD staging.
- Time to response.
- Maximal daily diarrhea (volume and frequency).
- Liver function tests.
- Cataract formation and IOP.
- TNF level.
- TPN consumption.
- Bone density.
- Diabetes – presence and control.
- Febrile episodes.
- Positive cultures.
- Days of antibiotic therapy.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Phase 3 Study to Evaluate the Place of Budesonide in the Treatment of GVHD|
|Study Start Date :||January 2001|
|Study Completion Date :||August 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00128739
|Hadassah Medical Organization,|
|Jerusalem, Israel, 91120|
|Principal Investigator:||Michael Y Shapira, MD||Hadassah Medical Organization|